Role of KCa3.1 Channels in CNS Diseases: A Concise Review
- PMID: 27549144
- DOI: 10.2174/1871527315666160822111913
Role of KCa3.1 Channels in CNS Diseases: A Concise Review
Abstract
KCa3.1 protein is part of a heterotetrameric voltage-independent potassium channel, the activity of which depends on the intracellular calcium binding to calmodulin. KCa3.1 is immensely significant in regulating immune responses and primarily expressed in cells of hematopoietic lineage. It is one of the attractive pharmacological targets that are known to inhibit neuroinflammation. KCa3.1 blockers mediate neuroprotection through multiple mechanisms, such as by targeting microglia-mediated neuronal killing. KCa3.1 modulators may provide alternative treatment options for neurological disorders like ischemic stroke, Alzheimer disease, glioblastoma multiforme, multiple sclerosis and spinal cord injury. This review is an attempt to draw attention towards KCa3.1 channel, which was never exploited to its full potential as a viable therapeutic candidate against various neurological disorders.
Similar articles
-
The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration.J Neurosci. 2007 Jan 3;27(1):234-44. doi: 10.1523/JNEUROSCI.3593-06.2007. J Neurosci. 2007. PMID: 17202491 Free PMC article.
-
Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:219-240. doi: 10.1146/annurev-pharmtox-010919-023420. Epub 2019 Jul 23. Annu Rev Pharmacol Toxicol. 2020. PMID: 31337271 Free PMC article. Review.
-
KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo.Cell Death Dis. 2013 Aug 15;4(8):e773. doi: 10.1038/cddis.2013.279. Cell Death Dis. 2013. PMID: 23949222 Free PMC article.
-
KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.Curr Neuropharmacol. 2018;16(5):618-626. doi: 10.2174/1570159X15666170630164226. Curr Neuropharmacol. 2018. PMID: 28676010 Free PMC article.
-
Ion channels on microglia: therapeutic targets for neuroprotection.CNS Neurol Disord Drug Targets. 2011 Feb;10(1):44-56. doi: 10.2174/187152711794488638. CNS Neurol Disord Drug Targets. 2011. PMID: 21143139 Review.
Cited by
-
Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer's Disease.Int J Mol Sci. 2023 May 22;24(10):9067. doi: 10.3390/ijms24109067. Int J Mol Sci. 2023. PMID: 37240413 Free PMC article. Review.
-
Imaging of KCa 3.1 Channels in Tumor Cells with PET and Small-Molecule Fluorescent Probes.ChemMedChem. 2023 Jan 17;18(2):e202200551. doi: 10.1002/cmdc.202200551. Epub 2022 Nov 22. ChemMedChem. 2023. PMID: 36315933 Free PMC article.
-
Synthesis and biological evaluation of PET tracers designed for imaging of calcium activated potassium channel 3.1 (KCa3.1) channels in vivo.RSC Adv. 2021 Sep 10;11(48):30295-30304. doi: 10.1039/d1ra03850h. eCollection 2021 Sep 6. RSC Adv. 2021. PMID: 35480282 Free PMC article.
-
Peripheral Blood Circular RNAs as a Biomarker for Major Depressive Disorder and Prediction of Possible Pathways.Front Neurosci. 2022 Mar 31;16:844422. doi: 10.3389/fnins.2022.844422. eCollection 2022. Front Neurosci. 2022. PMID: 35431783 Free PMC article.
-
Ion Channel Dysfunction in Astrocytes in Neurodegenerative Diseases.Front Physiol. 2022 Feb 9;13:814285. doi: 10.3389/fphys.2022.814285. eCollection 2022. Front Physiol. 2022. PMID: 35222082 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources